In high-risk gliomas, recurrent CNVs—such as chromosome 7/12 amplifications (EGFR, CDK4/MDM2) and chromosome 1/8/13 deletions (CHD5, DLC1, RB1)—play pivotal roles in promoting proliferation, immune evasion, and DNA repair defects. This evidence concerns the gene MDM2 and central nervous system cancer.